Quote:

---

why was only 2 doses insisted upon?

---

In March 2020 we were to have a trial that looked at 14 day mortality and we killed that at 82% saved!! How did that get changed to 28 day?

Quote:

---

The randomized, double-blind, placebo-controlled phase II study of leronlimab as treatment of COVID-19 is expected to include 75 patients from up to 10 treatment centers in the United States. CytoDyn has also filed for the initiation of a phase II/III trial for the treatment of severely ill patients with COVID-19. This double-blind trial is expected to enroll 342 patients and randomize them in a 2:1 ratio. The primary end point of this trial is the mortality rate at 14 days

---

And how about this safety hold on HIV????

Quote:

---

four ongoing HIV clinical trials where over 800 individuals received leronlimab, no drug-related deaths, serious injection site reactions, or drug–drug interactions were reported

---